

David J Kuter

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6154527/david-j-kuter-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

164
papers

6,606
citations

35
h-index

80
g-index

190
ext. papers

8,078
ext. citations

4.9
avg, IF

6.51
L-index

#	Paper	IF	Citations
164	Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study.. <i>American Journal of Hematology</i> , 2022 ,	7.1	4
163	Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.. <i>New England Journal of Medicine</i> , 2022 , 386, 1421-1431	59.2	2
162	The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. <i>Blood Reviews</i> , 2021 , 100909	11.1	3
161	Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study). <i>Blood</i> , 2021 , 138, 2088-2088	2.2	0
160	Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia. <i>Blood</i> , 2021 , 138, 14-14	2.2	2
159	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. <i>Blood</i> , 2021 , 138, 586-586		0
158	LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia. <i>Blood</i> , 2021 , 138, 1010-1010	2.2	2
157	Novel therapies for immune thrombocytopenia. <i>British Journal of Haematology</i> , 2021 ,	4.5	4
156	Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. <i>Liver International</i> , 2021 ,	7.9	4
155	An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the INHIBIT-Bleed study. <i>Haematologica</i> , 2021 , 106, 2161-2169	6.6	26
154	Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria. <i>American Journal of Hematology</i> , 2021 , 96, E235-E237	7.1	1
153	How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. <i>Blood</i> , 2021 , 137, 2736-2744	2.2	4
152	Exacerbation of immune thrombocytopenia following COVID-19 vaccination. <i>British Journal of Haematology</i> , 2021 , 195, 365-370	4.5	27
151	A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. <i>Haematologica</i> , 2021 , 106, 1148-1157	6.6	23
150	An evaluation of avatrombopag for the treatment of thrombocytopenia. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 273-280	4	7
149	Lessons Learned Using Real-World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 1570-1578	6.1	
148	Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. <i>Blood Reviews</i> , 2021 , 49, 100811	11.1	4

147	Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2021 , 96, 1563-1568	7.1	0
146	SARS-CoV-2 Vaccination and Immune Thrombocytopenia in de novo and pre-existing ITP patients. <i>Blood</i> , 2021 ,	2.2	10
145	Case 38-2020: A 52-Year-Old Man with Cancer and Acute Hypoxemia. <i>New England Journal of Medicine</i> , 2020 , 383, 2372-2383	59.2	1
144	The role of romiplostim for pediatric patients with immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2020 , 11, 2040620720912992	5.7	8
143	COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. <i>Blood</i> , 2020 , 136, 489-500	2.2	642
142	Congenital thrombotic thrombocytopenic purpura (TTP) with placental abruption despite maternal improvement: a case report. <i>BMC Pregnancy and Childbirth</i> , 2020 , 20, 365	3.2	1
141	Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. <i>American Journal of Hematology</i> , 2020 , 95, 643-651	7.1	9
140	Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia. <i>American Journal of Hematology</i> , 2020 , 95, 1180	7.1	12
139	Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00118	4.2	0
138	Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry. <i>British Journal of Haematology</i> , 2020 , 190, 923-932	4.5	4
137	Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress. <i>Blood</i> , 2020 , 136, 6-7	2.2	
136	Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders and Tendencies: Methodology for Delphi Consensus Recommendations. <i>Blood</i> , 2020 , 136, 29-29	2.2	
135	Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19. <i>Blood</i> , 2020 , 136, 4-5	2.2	
134	Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up. <i>Blood</i> , 2020 , 136, 24-25	2.2	2
133	Eighteen-Month Interim Analysis of Efficacy and Safety of Givosiran, an RNAi Therapeutic for Acute Hepatic Porphyria, in the Envision Open Label Extension. <i>Blood</i> , 2020 , 136, 13-13	2.2	1
132	Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia. <i>Blood</i> , 2020 , 136, 13-14	2.2	3
131	Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia. <i>Blood</i> , 2020 , 136, 14-15	2.2	7
130	Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study. <i>Blood</i> , 2020 , 136, 1-3	2.2	4

129	Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 275-288	5.3	23
128	Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. <i>American Journal of Hematology</i> , 2020 , 95, 178-187	7.1	45
127	Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. <i>Blood Reviews</i> , 2020 , 41, 100648	11.1	109
126	Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. <i>Leukemia Research</i> , 2020 , 98, 106459	2.7	9
125	Scoring system to facilitate diagnosis of Gaucher disease. <i>Internal Medicine Journal</i> , 2020 , 50, 1538-1546	1.6	2
124	Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. <i>Expert Review of Hematology</i> , 2020 , 13, 1319-1332	2.8	4
123	Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19). <i>American Journal of Hematology</i> , 2020 , 95, 1479-1485	7.1	13
122	Preparing patients with immune thrombocytopenia for surgery: what are the options?. <i>Lancet Haematology</i> , 2020 , 7, e626-e627	14.6	1
121	Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 219-225	2	5
120	Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1178-1180	4.4	2
119	Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy. <i>Blood Cells, Molecules, and Diseases</i> , 2020 , 82, 102418	2.1	0
118	A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. <i>Blood Advances</i> , 2020 , 4, 9-18	7.8	26
117	Lactate dehydrogenase is elevated in immune thrombocytopenia and inversely correlates with platelet count. <i>British Journal of Haematology</i> , 2019 , 187, e61-e64	4.5	3
116	Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2019 , 10, 2040620719841735	5.7	36
115	Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease. <i>International Journal of Laboratory Hematology</i> , 2019 , 41, 325-330	2.5	
114	Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. <i>British Journal of Haematology</i> , 2019 , 185, 503-513	4.5	33
113	Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 579-584	2	6
112	Inhibition of the Classical Pathway of Complement with Sutimlimab in Chronic Immune Thrombocytopenic Purpura Patients without Adequate Response to Two or More Prior Therapies. <i>Blood</i> , 2019 , 134, 898-898	2.2	4

111	Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia. <i>Blood</i> , 2019 , 134, 87-87	2.2	11
110	Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study. <i>Blood</i> , 2019 , 134, 3518-3518	2.2	1
109	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. <i>Blood</i> , 2019 , 134, 4172-4172	2.2	4
108	Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia. <i>Blood</i> , 2019 , 134, 895-895	2.2	0
107	Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study. <i>Blood</i> , 2019 , 134, LBA-2-LBA-2	2.2	8
106	An International Multicenter Study of Intravenous Bevacizumab for the Treatment of Chronic Bleeding and Anemia in Hereditary Hemorrhagic Telangiectasia: The Inhibit-Bleed Study. <i>Blood</i> , 2019 , 134, 1060-1060	2.2	
105	Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia. <i>Blood</i> , 2019 , 134, 4800-4800	2.2	
104	Recurrence of Acute Intermittent Porphyria After Liver Transplantation. <i>Annals of Internal Medicine</i> , 2019 , 170, 904-905	8	6
103	Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance. <i>Blood Advances</i> , 2019 , 3, 3515-3521	7.8	10
102	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Advances</i> , 2019 , 3, 3780-3817	7.8	267
101	American Society of Hematology 2019 guidelines for immune thrombocytopenia. <i>Blood Advances</i> , 2019 , 3, 3829-3866	7.8	299
100	Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative. <i>Internal Medicine Journal</i> , 2019 , 49, 578-591	1.6	19
99	Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. <i>Annals of Hematology</i> , 2019 , 98, 581-588	3	22
98	Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. <i>American Journal of Hematology</i> , 2019 , 94, 149-161	7.1	35
97	General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors 2019 , 108-126		4
96	Hepatocellular carcinoma in Gaucher disease: an international case series. <i>Journal of Inherited Metabolic Disease</i> , 2018 , 41, 819-827	5.4	24
95	The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. <i>Haematologica</i> , 2018 , 103, e169-e172	6.6	37
94	An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2673-2677	3.8	15

93	Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study. <i>Blood</i> , 2018 , 132, 3612-3612	2.2	4
92	Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database. <i>Blood</i> , 2018 , 132, 3284-3284	2.2	1
91	Assessment of Romiplostim Immunogenicity in Adult Patients in Clinical Trials and in a Global Registry. <i>Blood</i> , 2018 , 132, 2427-2427	2.2	3
90	Absence of Plasma Gastric Biomarker Elevations with Chronic Dosing of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Patients with Chronic Immune Thrombocytopenia in Phase 3 Trials. <i>Blood</i> , 2018 , 132, 3740-3740	2.2	0
89	Antiplatelet Antibody Testing in Immune Thrombocytopenia and Evans Syndrome: Longitudinal Serologic Evolution and Relation to Clinical Features. <i>Blood</i> , 2018 , 132, 1137-1137	2.2	4
88	Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study. <i>Blood</i> , 2018 , 132, 3285-3285	2.2	
87	Open-Label, Expanded Access Study of Taliglucerase Alfa in Patients with Gaucher Disease Requiring Enzyme Replacement Therapy. <i>Blood</i> , 2018 , 132, 3755-3755	2.2	
86	Systemic Bevacizumab for the Treatment of Chronic Bleeding in Hereditary Hemorrhagic Telangiectasia. <i>Blood</i> , 2018 , 132, 852-852	2.2	
85	Thrombopoietin Level Predicts Response to Treatment with Eltrombopag and Romiplostim in Immune Thrombocytopenia. <i>Blood</i> , 2018 , 132, 734-734	2.2	
84	Management of disseminated intravascular coagulation in a patient with hepatic angiosarcoma: A case report. <i>Medicine (United States)</i> , 2018 , 97, e13321	1.8	7
83	Infections and vaccination in hereditary hemorrhagic telangiectasia: microbiological evidence-based considerations. <i>Haematologica</i> , 2018 , 103, e492-e495	6.6	6
82	Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. <i>American Journal of Hematology</i> , 2018 , 93, 1501-1508	7.1	35
81	Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies. <i>British Journal of Haematology</i> , 2018 , 183, 466-478	4.5	10
80	Romiplostim for the management of perioperative thrombocytopenia. <i>British Journal of Haematology</i> , 2018 , 182, 106-113	4.5	27
79	Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. <i>Haematologica</i> , 2018 , 103, 1433-1443	6.6	70
78	Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. <i>British Journal of Haematology</i> , 2018 , 183, 168	4.5	17
77	Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2017 , 92, 730-738	7.1	32
76	Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. <i>Molecular Genetics and Metabolism</i> , 2017 , 122, 122-129	3.7	27

75	Markers of Autoimmunity in Immune Thrombocytopenia: Prevalence and Prognostic Significance. <i>Blood</i> , 2016 , 128, 1363-1363	2.2	1
74	Romiplostim for Treatment and Prevention of Chemotherapy-Associated Thrombocytopenia. <i>Blood</i> , 2016 , 128, 3748-3748	2.2	2
73	Key Presenting Signs and Patient Co-Variables in Early Diagnosis of Type 3 Gaucher Disease: A Global Delphi Consensus Initiative. <i>Blood</i> , 2016 , 128, 4886-4886	2.2	1
72	Safety and Efficacy of PRTX-100, a Highly Purified Form of Staphylococcal Protein A, in Patients with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2016 , 128, 4929-4929	2.2	5
71	Health care resource utilization (HCRU) in relapsed/refractory multiple myeloma (RRMM): Results from PREAMBLE.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6621-6621	2.2	1
70	A Global Delphi Consensus Initiative for Early Diagnosis of Gaucher Disease: Key Presenting Signs and Patient Co-Variables in Type 1 Disease. <i>Blood</i> , 2016 , 128, 3676-3676	2.2	
69	A Global Delphi Consensus Initiative for Early Diagnosis of Gaucher Disease: Barriers, Their Resolution and the Impact on Patients. <i>Blood</i> , 2016 , 128, 4885-4885	2.2	
68	An Ongoing, Observational Cohort Study in Multiple Myeloma (PREAMBLE): Preliminary Efficacy Analyses in Patients with 1 Line of Prior Therapy. <i>Blood</i> , 2016 , 128, 2403-2403	2.2	
67	FF-10102-01: A Novel, Highly Selective Spleen Tyrosine Kinase Inhibitor, to Be in Clinical Application for Treatment of Autoimmune Diseases and B-Cell Malignancies. <i>Blood</i> , 2016 , 128, 3745-3745	2.2	
66	Pure White Cell Aplasia and Necrotizing Myositis. <i>Case Reports in Hematology</i> , 2016 , 2016, 4161679	0.7	1
65	What is the role of novel thrombopoietic agents in the management of acute leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2016 , 29, 372-378	4.2	5
64	Remissions after long-term use of romiplostim for immune thrombocytopenia. <i>Haematologica</i> , 2016 , 101, e476-e478	6.6	16
63	Romiplostim in the management of the thrombocytopenic surgical patient. <i>Transfusion</i> , 2015 , 55, 2505-109		20
62	Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. <i>International Journal of Hematology</i> , 2015 , 101, 255-63	2.3	40
61	An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival. <i>Blood</i> , 2015 , 126, 2093-2093	2.2	1
60	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. <i>Blood</i> , 2014 , 123, 3887-94	2.2	78
59	TPO concentrations and response to romiplostim. <i>American Journal of Hematology</i> , 2014 , 89, 1155-6	7.1	6
58	Milestones in understanding platelet production: a historical overview. <i>British Journal of Haematology</i> , 2014 , 165, 248-58	4.5	72

57	Romiplostim in Management of the Thrombocytopenic Surgical Patient. <i>Blood</i> , 2014 , 124, 1459-1459	2.2	
56	The biology of thrombopoietin and thrombopoietin receptor agonists. <i>International Journal of Hematology</i> , 2013 , 98, 10-23	2.3	142
55	Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. <i>Blood Cells, Molecules, and Diseases</i> , 2013 , 51, 116-24	2.1	51
54	Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. <i>British Journal of Haematology</i> , 2013 , 161, 411-23	4.5	180
53	Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. <i>American Journal of Hematology</i> , 2013 , 88, 1041-41	7.1	45
52	Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. <i>American Journal of Hematology</i> , 2012 , 87, 558-61	7.1	52
51	What is the potential for thrombopoietic agents in acute leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2011 , 24, 553-8	4.2	10
50	Thrombopoietin Levels May Predict Responsiveness to Therapy with Thrombopoietin Agonists Among Patients with Immune Thrombocytopenic Purpura,. <i>Blood</i> , 2011 , 118, 3288-3288	2.2	4
49	Patient Reported Outcomes Comparison of Chronic Immune Thrombocytopenia (ITP) Patients Switched to Promacta and Nplate. <i>Blood</i> , 2011 , 118, 2220-2220	2.2	
48	Miglustat Therapy in Type 1 Gaucher Disease: Long-Term Treatment Experience From a Multicenter, Retrospective Cohort Study,. <i>Blood</i> , 2011 , 118, 3207-3207	2.2	
47	A Double-Blind, Placebo-Controlled, and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ono-7746 in Healthy Subjects. <i>Blood</i> , 2011 , 118, 4828-4828	2.2	
46	Single Oral Doses of a Novel Thrombopoietin Mimetic ONO-7746 Increase Platelet Counts In Healthy Subjects. <i>Blood</i> , 2011 , 118, 4827-4827	2.2	
45	Romiplostim. <i>Cancer Treatment and Research</i> , 2011 , 157, 267-88	3.5	24
44	Romiplostim or standard of care in patients with immune thrombocytopenia. <i>New England Journal of Medicine</i> , 2010 , 363, 1889-99	59.2	313
43	Biology and chemistry of thrombopoietic agents. <i>Seminars in Hematology</i> , 2010 , 47, 243-8	4	83
42	Efficacy, Safety and Tolerability of E5501 (AKR501) In a 6-Month Extension Study In Subjects with Chronic Immune Thrombocytopenia (ITP).. <i>Blood</i> , 2010 , 116, 3695-3695	2.2	2
41	Analysis of Mortality Rates During Romiplostim Clinical Studies of Patients (Pts) with Immune Thrombocytopenia (ITP).. <i>Blood</i> , 2010 , 116, 3701-3701	2.2	3
40	Patient Quality of Life (QOL) In Nonsplenectomized Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim or Medical Standard of Care (SOC). <i>Blood</i> , 2010 , 116, 569-569	2.2	1

39	Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study. <i>Blood</i> , 2010 , 116, 68-68	2.2	8
38	A Randomized, Double-Blind, Placebo-Controlled Phase II Trial on the Efficacy, Safety and Tolerability of E5501 (AKR501) In Subjects with Chronic Immune Thrombocytopenia (ITP). <i>Blood</i> , 2010 , 116, 71-71	2.2	4
37	The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.. <i>Blood</i> , 2010 , 116, 3702-3702	2.2	
36	Thrombin Generation During Abdominal Surgical Procedures: Effect of Prophylactic Anticoagulation Therapy. <i>Blood</i> , 2010 , 116, 3183-3183	2.2	
35	Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. <i>Blood</i> , 2009 , 114, 3748-56	2.2	152
34	New thrombopoietic growth factors. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9 Suppl 3, S347-56		33
33	Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. <i>Annual Review of Medicine</i> , 2009 , 60, 193-206	17.4	149
32	Thrombopoietin and platelet production in chronic immune thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2009 , 23, 1193-211	3.1	45
31	Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.. <i>Blood</i> , 2009 , 114, 679-679	2.2	2
30	Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.. <i>Blood</i> , 2009 , 114, 681-681	2.2	2
29	New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. <i>European Journal of Haematology</i> , 2008 , 80, 9-18	3.8	33
28	Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. <i>Lancet, The</i> , 2008 , 371, 395-403	40	663
27	Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study. <i>Blood</i> , 2008 , 112, 402-402	2.2	7
26	Gestational Platelet Trends and Outcomes in Women with Myeloproliferative Disorders Characterized by Thrombocytosis. <i>Blood</i> , 2008 , 112, 5251-5251	2.2	
25	Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. <i>British Journal of Haematology</i> , 2007 , 139, 351-62	4.5	192
24	New thrombopoietic growth factors. <i>Blood</i> , 2007 , 109, 4607-16	2.2	272
23	A Comparative Proteomic Analysis of Platelets from Healthy Human Patients and Chronic ITP Patients Receiving AMG 531, a Thrombopoiesis-Stimulating Protein.. <i>Blood</i> , 2007 , 110, 1313-1313	2.2	2
22	The Incidence of Thrombosis in Patients with Isolated Heparin Induced Thrombocytopenia.. <i>Blood</i> , 2006 , 108, 1049-1049	2.2	1

21	Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura.. <i>Blood</i> , 2006 , 108, 3982-3982	2.2	15
20	The Identification of Hypercoagulable Markers in Patients with Malignant Gliomas and Venous Thromboembolism.. <i>Blood</i> , 2006 , 108, 4097-4097	2.2	1
19	Long-Term Follow-Up of Monoclonal Gammopathies in Gaucher Disease Patients on Enzyme Replacement Therapy.. <i>Blood</i> , 2006 , 108, 3336-3336	2.2	
18	Thrombotic complications of central venous catheters in cancer patients. <i>Oncologist</i> , 2004 , 9, 207-16	5.7	183
17	In Reply: Low-Dose Warfarin Prophylaxis for Catheter-Associated Thrombosis in Cancer Patients. Can It Be Safely Associated with 5-Fluorouracil-Based Chemotherapy?. <i>Oncologist</i> , 2004 , 9, 596-596	5.7	2
16	Fondaparinux in the Treatment of Heparin-Induced Thrombocytopenia.. <i>Blood</i> , 2004 , 104, 1775-1775	2.2	14
15	Phase II Trial of Single Agent Bortezomib (VELCADE [®]) in Patients with Previously Untreated Multiple Myeloma (MM).. <i>Blood</i> , 2004 , 104, 336-336	2.2	28
14	Apoptosis in platelets during ex vivo storage. <i>Vox Sanguinis</i> , 2002 , 83 Suppl 1, 311-3	3.1	19
13	Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. <i>Blood</i> , 2002 , 100, 3457-69	2.2	301
12	Thrombocytopenia caused by the development of antibodies to thrombopoietin. <i>Blood</i> , 2001 , 98, 3241-8	2.2	567
11	Thrombopoietin therapy increases platelet yields in healthy platelet donors. <i>Blood</i> , 2001 , 98, 1339-45	2.2	81
10	The end is just the beginning: megakaryocyte apoptosis and platelet release. <i>International Journal of Hematology</i> , 2001 , 74, 365-74	2.3	44
9	The mechanism of apoptosis in human platelets during storage. <i>Transfusion</i> , 2000 , 40, 1320-9	2.9	138
8	The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. <i>British Journal of Haematology</i> , 2000 , 111, 943-953	4.5	1
7	Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. <i>British Journal of Haematology</i> , 1999 , 106, 345-56	4.5	127
6	Cancer, Coagulation, and Anticoagulation. <i>Oncologist</i> , 1999 , 4, 443-449	5.7	40
5	Apheresis platelets: emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose. <i>Journal of Clinical Apheresis</i> , 1998 , 13, 114-9	3.2	29
4	The use of PEG-rhuMGDF in platelet apheresis. <i>Stem Cells</i> , 1998 , 16 Suppl 2, 231-42	5.8	18

3	Apheresis platelets: Emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose 1998 , 13, 114		3
2	The physiology of platelet production. <i>Stem Cells</i> , 1996 , 14 Suppl 1, 88-101	5.8	98
1	Thrombopoietin: Biology and Clinical Applications. <i>Oncologist</i> , 1996 , 1, 98-106	5.7	28